tetano
Editor, Senior Moderator
Nat Commun
. 2021 Oct 20;12(1):6097.
doi: 10.1038/s41467-021-26354-0.
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Pauline Maisonnasse[SUP] #[/SUP][SUP] 1 [/SUP], Yoann Aldon[SUP] #[/SUP][SUP] 2 [/SUP], Aurélien Marc[SUP] 3 [/SUP], Romain Marlin[SUP] 1 [/SUP], Nathalie Dereuddre-Bosquet[SUP] 1 [/SUP], Natalia A Kuzmina[SUP] 4 5 [/SUP], Alec W Freyn[SUP] 6 [/SUP], Jonne L Snitselaar[SUP] 2 [/SUP], Antonio Gonçalves[SUP] 3 [/SUP], Tom G Caniels[SUP] 2 [/SUP], Judith A Burger[SUP] 2 [/SUP], Meliawati Poniman[SUP] 2 [/SUP], Ilja Bontjer[SUP] 2 [/SUP], Virginie Chesnais[SUP] 7 [/SUP], Ségolène Diry[SUP] 7 [/SUP], Anton Iershov[SUP] 7 [/SUP], Adam J Ronk[SUP] 4 5 [/SUP], Sonia Jangra[SUP] 6 [/SUP], Raveen Rathnasinghe[SUP] 6 8 [/SUP], Philip J M Brouwer[SUP] 2 [/SUP], Tom P L Bijl[SUP] 2 [/SUP], Jelle van Schooten[SUP] 2 [/SUP], Mitch Brinkkemper[SUP] 2 [/SUP], Hejun Liu[SUP] 9 [/SUP], Meng Yuan[SUP] 9 [/SUP], Chad E Mire[SUP] 5 10 [/SUP], Mariëlle J van Breemen[SUP] 2 [/SUP], Vanessa Contreras[SUP] 1 [/SUP], Thibaut Naninck[SUP] 1 [/SUP], Julien Lemaître[SUP] 1 [/SUP], Nidhal Kahlaoui[SUP] 1 [/SUP], Francis Relouzat[SUP] 1 [/SUP], Catherine Chapon[SUP] 1 [/SUP], Raphaël Ho Tsong Fang[SUP] 1 [/SUP], Charlene McDanal[SUP] 11 [/SUP], Mary Osei-Twum[SUP] 12 [/SUP], Natalie St-Amant[SUP] 12 [/SUP], Luc Gagnon[SUP] 12 [/SUP], David C Montefiori[SUP] 11 [/SUP], Ian A Wilson[SUP] 9 [/SUP], Eric Ginoux[SUP] 7 [/SUP], Godelieve J de Bree[SUP] 13 [/SUP], Adolfo García-Sastre[SUP] 6 14 15 16 [/SUP], Michael Schotsaert[SUP] 6 16 [/SUP], Lynda Coughlan[SUP] 6 17 [/SUP], Alexander Bukreyev[SUP] 4 5 10 [/SUP], Sylvie van der Werf[SUP] 18 19 [/SUP], Jérémie Guedj[SUP] 3 [/SUP], Rogier W Sanders[SUP] 20 21 [/SUP], Marit J van Gils[SUP] 22 [/SUP], Roger Le Grand[SUP] 23 [/SUP]
Affiliations
Abstract
Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent against the B.1.1.7 isolate. In both prophylactic and therapeutic settings, SARS-CoV-2 remains undetectable in the lungs of treated hACE2 mice. Therapeutic treatment also causes a reduction in viral loads in the lungs of Syrian hamsters. When administered at 10 mg kg-1 one day prior to a high dose SARS-CoV-2 challenge in cynomolgus macaques, COVA1-18 shows very strong antiviral activity in the upper respiratory compartments. Using a mathematical model, we estimate that COVA1-18 reduces viral infectivity by more than 95% in these compartments, preventing lymphopenia and extensive lung lesions. Our findings demonstrate that COVA1-18 has a strong antiviral activity in three preclinical models and could be a valuable candidate for further clinical evaluation.
. 2021 Oct 20;12(1):6097.
doi: 10.1038/s41467-021-26354-0.
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Pauline Maisonnasse[SUP] #[/SUP][SUP] 1 [/SUP], Yoann Aldon[SUP] #[/SUP][SUP] 2 [/SUP], Aurélien Marc[SUP] 3 [/SUP], Romain Marlin[SUP] 1 [/SUP], Nathalie Dereuddre-Bosquet[SUP] 1 [/SUP], Natalia A Kuzmina[SUP] 4 5 [/SUP], Alec W Freyn[SUP] 6 [/SUP], Jonne L Snitselaar[SUP] 2 [/SUP], Antonio Gonçalves[SUP] 3 [/SUP], Tom G Caniels[SUP] 2 [/SUP], Judith A Burger[SUP] 2 [/SUP], Meliawati Poniman[SUP] 2 [/SUP], Ilja Bontjer[SUP] 2 [/SUP], Virginie Chesnais[SUP] 7 [/SUP], Ségolène Diry[SUP] 7 [/SUP], Anton Iershov[SUP] 7 [/SUP], Adam J Ronk[SUP] 4 5 [/SUP], Sonia Jangra[SUP] 6 [/SUP], Raveen Rathnasinghe[SUP] 6 8 [/SUP], Philip J M Brouwer[SUP] 2 [/SUP], Tom P L Bijl[SUP] 2 [/SUP], Jelle van Schooten[SUP] 2 [/SUP], Mitch Brinkkemper[SUP] 2 [/SUP], Hejun Liu[SUP] 9 [/SUP], Meng Yuan[SUP] 9 [/SUP], Chad E Mire[SUP] 5 10 [/SUP], Mariëlle J van Breemen[SUP] 2 [/SUP], Vanessa Contreras[SUP] 1 [/SUP], Thibaut Naninck[SUP] 1 [/SUP], Julien Lemaître[SUP] 1 [/SUP], Nidhal Kahlaoui[SUP] 1 [/SUP], Francis Relouzat[SUP] 1 [/SUP], Catherine Chapon[SUP] 1 [/SUP], Raphaël Ho Tsong Fang[SUP] 1 [/SUP], Charlene McDanal[SUP] 11 [/SUP], Mary Osei-Twum[SUP] 12 [/SUP], Natalie St-Amant[SUP] 12 [/SUP], Luc Gagnon[SUP] 12 [/SUP], David C Montefiori[SUP] 11 [/SUP], Ian A Wilson[SUP] 9 [/SUP], Eric Ginoux[SUP] 7 [/SUP], Godelieve J de Bree[SUP] 13 [/SUP], Adolfo García-Sastre[SUP] 6 14 15 16 [/SUP], Michael Schotsaert[SUP] 6 16 [/SUP], Lynda Coughlan[SUP] 6 17 [/SUP], Alexander Bukreyev[SUP] 4 5 10 [/SUP], Sylvie van der Werf[SUP] 18 19 [/SUP], Jérémie Guedj[SUP] 3 [/SUP], Rogier W Sanders[SUP] 20 21 [/SUP], Marit J van Gils[SUP] 22 [/SUP], Roger Le Grand[SUP] 23 [/SUP]
Affiliations
- PMID: 34671037
- DOI: 10.1038/s41467-021-26354-0
Abstract
Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent against the B.1.1.7 isolate. In both prophylactic and therapeutic settings, SARS-CoV-2 remains undetectable in the lungs of treated hACE2 mice. Therapeutic treatment also causes a reduction in viral loads in the lungs of Syrian hamsters. When administered at 10 mg kg-1 one day prior to a high dose SARS-CoV-2 challenge in cynomolgus macaques, COVA1-18 shows very strong antiviral activity in the upper respiratory compartments. Using a mathematical model, we estimate that COVA1-18 reduces viral infectivity by more than 95% in these compartments, preventing lymphopenia and extensive lung lesions. Our findings demonstrate that COVA1-18 has a strong antiviral activity in three preclinical models and could be a valuable candidate for further clinical evaluation.